FORM	4
------	---

(Duint on Toma Day

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

SEC 1474 (9-02)

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Chin Mark	2. Issuer Name <b>a</b> Iterum Therape	utics plc	[ITR	.M]		5. Relationship of Reporting Perso (Check all appl _X_Director Officer (give title below)					
C/O ITERUM THE 2, FL. 3, HARCOU ST.	3. Date of Earliest 05/24/2019	Transaction	(1010)	ntn/Day/ i	ear)			,			
DUBLIN, L2 2	4. If Amendment, I	Date Origina	al Fil	ed(Month/D	ay/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)				(Instr. 8)	tion	(A) or Disposed of (D) H (Instr. 3, 4 and 5) H			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	Ownership Indirect Form: Benefic	Beneficial
			(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Ordinary Shares		05/24/2019		М		6,154	А	<u>(1)</u>	6,154	D	
Ordinary Shares									1,089,903	I	By Arix Bioscience Holdings Ltd. <sup>(2)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	ion )	5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial
				Code	v	(A)	(D)	Date Exercisable	Expiration Date		Amount or Number of Shares				
Restricted Stock Units	<u>(1)</u>	05/24/2019		М			6,154	<u>(3)</u>	<u>(3)</u>	Ordinary Shares	6,154	\$ 0	0	D	

### **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Chin Mark C/O ITERUM THERAPEUTICS PLC, BLK 2 FL. 3, HARCOURT CENTRE, HARCOURT ST. DUBLIN, L2 2	Х						

## Signatures

05/27/2019

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units.
- (2) The reporting person is an Investment Director for Arix Bioscience Holdings Ltd.
- (3) On May 24, 2018, the reporting person was granted an award of 6,154 restricted stock units, which vested on May 24, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.